Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.96 |
| ▸ | CA4 | P22748 | 1/20 | 0.96 |
| ▸ | ENO1 | P06733 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | OTC | P00480 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pala SCHEMBL11121904 | 1.00 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| Pala SCHEMBL59449 | 0.98 | CA2 (1.00) | CA2CA4ENO1MEN1LMNA | |
| Sparfosic Acid SCHEMBL3514530 | 0.98 | CA2 (1.00) | CA2CA4ENO1MEN1LMNA | |
| Sparfosic Acid SCHEMBL31237824 | 0.96 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| Pala SCHEMBL31389020 | 0.96 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| SCHEMBL7747522 | 0.84 | CA2 (0.74) | CA2CA4ENO1MEN1KMT2A | |
| Pala SCHEMBL3514468 | 0.83 | CA2 (0.72) | CA2CA4FOLH1OTC | |
| SCHEMBL3513056 | 0.82 | CA2 (0.71) | CA2CA4HPGDFOLH1GGH | |
| SCHEMBL12990268 | 0.82 | CA2 (0.71) | CA2CA4HPGDFOLH1GGH | |
| Sparfosic Acid SCHEMBL28558641 | 0.82 | CA2 (0.72) | CA2CA4ENO1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4166558-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4- [(METHYLAMINO)METHYL]PHENYL}-1 ,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3- CD]INDOL-6-ONE | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3650023-A1 | COMPOSITIONS FOR TREATING CANCERS | Aptose Biosciences Inc. (CA) | 2020-05-13 | — | — | EP | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3150610-B1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10278974-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | PFIZER INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180092925-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER INC. | 2018-04-05 | — | — | US | disclosed |
| US-9861638-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | PFIZER INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170335400-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | APTOSE BIOSCIENCES INC. (CA) | 2017-11-23 | — | — | US | disclosed |
| EP-3233829-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | Pfizer Inc (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | Agouron Pharmaceuticals,Inc. | 2005-04-28 | — | — | US | disclosed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021553-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021554-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005009997-A1 | 3,5 DISUBSTITUTED INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MEDIATING OR INHIBITING CELL PROLIFERATION | PFIZER INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040224988-A1 | Dosage forms and methods of treatment using VEGFR inhibitors | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004087152-A1 | DOSAGE FORMS COMPRISING AG013736 | PFIZER INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | CCNA1, PGF, CCNA2 | CA2 1810/4885CA4 2377/4885ENO1 2945/4885 |
| US-20180092925-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | BRCA1, IMPA1, PARP1 | CA2 1304/4885CA4 1144/4885ENO1 4250/4885 |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | CA2 1436/4885CA4 2863/4885ENO1 3414/4885 |
| US-20170335400-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | NFXL1, MCL1, CBX2 | CA2 3397/4885CA4 3890/4885ENO1 4344/4885 |
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDKL3 | CA2 1666/4885CA4 2217/4885ENO1 3675/4885 |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | CA2 1335/4885CA4 1300/4885ENO1 1373/4885 |
| US-10278974-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | BRCA1, IMPA1, PARP1 | CA2 1304/4885CA4 1144/4885ENO1 4250/4885 |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | CA2 2355/4885CA4 2589/4885ENO1 3415/4885 |
| US-20040224988-A1 | Dosage forms and methods of treatment using VEGFR inhibitors | FLT1, FLT4, KDR | CA2 981/4885CA4 724/4885ENO1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.